GUANGJI PHARMA.(SZ:000952) Cai Jing Wang·2025-07-03 02:36Core Viewpoint - Guangji Pharmaceutical has received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, leading to an investigation and potential penalties [1][2]. Group 1: Violation Details - From January to September 2022, Guangji Pharmaceutical's subsidiary, Hubei Guangji Pharmaceutical Jikang Pharmaceutical Co., Ltd., engaged in sales activities without having control over the goods, resulting in improper revenue recognition using the gross method instead of the net method [1][2]. - The improper revenue recognition led to overstated revenues of 45.6016 million yuan, 136.86 million yuan, and 138.2004 million yuan for the first quarter, half-year, and third quarter of 2022, respectively, accounting for 25.49%, 26.68%, and 20.49% of the reported revenues for those periods [1][2]. Group 2: Responsible Parties - Ruan Shu, the then Chairman of Guangji Pharmaceutical, failed to adequately oversee the sales activities and signed off on the financial reports, which constitutes a violation of the Securities Law [2][3]. - Hu Mingfeng, the then Chief Financial Officer and Chairman of Jikang Pharmaceutical, also did not exercise due diligence in the accounting treatment of the sales activities and signed the financial reports, making him directly responsible for the violations [3]. Group 3: Proposed Penalties - The CSRC plans to impose a warning and a fine of 1.5 million yuan on Guangji Pharmaceutical, along with a warning and fines of 800,000 yuan each for Ruan Shu and Hu Mingfeng [3]. - The company has expressed sincere apologies to investors and committed to enhancing compliance awareness and improving operational standards to ensure accurate and timely information disclosure in the future [3].